SCA
GILD icon

SAC Capital Advisors’s Gilead Sciences GILD Stock Holding History

SAC Capital Advisors’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-207,778
Closed -$14.7M – 402
2014
Q1 		$14.7M Buy
207,778
+144,778
+230% +$11.4M 0.08% 333
2013
Q4 		$4.73M Buy
63,000
+13,668
+28% +$952K 0.03% 506
2013
Q3 		$3.1M Sell
49,332
-2,261,801
-98% -$135M 0.02% 634
2013
Q2 		$118M Buy
+2,311,133
New +$120M 0.65% 19

Other funds holding GILD

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

SAC Capital Advisors's GILD Position: Q2 2014 in Review

SAC Capital Advisors sold out of Gilead Sciences (GILD) in Q2 2014, closing a stake of 207,778 shares — an estimated $14.7M sold.

SAC Capital Advisors first reported a position in GILD in Q2 2013 and held it in 4 quarters. The position peaked at $118M in Q2 2013. 1,262 funds tracked by Wall St. Rank hold GILD as of Q2 2014.

  • SAC Capital Advisors reported no remaining Gilead Sciences position as of Q2 2014 after selling out during the quarter.
  • SAC Capital Advisors sold 207,778 Gilead Sciences shares in Q2 2014, an estimated $14.7M.
  • SAC Capital Advisors first reported a position in Gilead Sciences in Q2 2013 and held it in 4 quarters.
  • SAC Capital Advisors's Gilead Sciences position peaked at $118M in Q2 2013.
  • 1,262 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2014.

Based on SAC Capital Advisors's 13F filing for Q2 2014.